Dendritic Cell Vaccines: Sipuleucel-T and Other Approaches

Nicholas M. Durham, Charles G. Drake

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The idea of a preventive vaccine against cancer has been extremely attractive because of the immune system's ability to develop specific and long-lasting immunological memory. Dendritic cells, which present antigen to T cells, sit at a critical point in the activation of the immune system because they are able to activate both B cells and T cells. The first DC vaccines were tested in humans in 1998. In 2010 the first DC vaccine was FDA approved for treatment of patients with advanced prostate cancer. This vaccine showed a survival advantage of 4.3 months. This vaccine was extremely safe, with low rates of adverse events. In this chapter we discuss the history of DC vaccines, the development of DC vaccines including Sipuleucel-T, and the future directions of DC vaccines. This includes strategies for combining DC vaccines with other therapies, including hormone therapy, additional immunotherapy, and chemotherapy.

Original languageEnglish (US)
Title of host publicationCancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition
PublisherElsevier Inc.
Pages273-286
Number of pages14
ISBN (Print)9780123942968
DOIs
StatePublished - Jul 2013

Fingerprint

Dendritic Cells
Vaccines
Immune System
Immunologic Memory
T-Lymphocytes
Cancer Vaccines
sipuleucel-T
Immunotherapy
Prostatic Neoplasms
B-Lymphocytes
Therapeutics
History
Hormones
Antigens
Drug Therapy
Survival

Keywords

  • Cancer
  • Dendritic cells
  • Hormone therapy
  • Immunotherapy
  • Lymphocyte
  • Sipuleucel-T
  • Vaccine

ASJC Scopus subject areas

  • Medicine(all)
  • Dentistry(all)

Cite this

Durham, N. M., & Drake, C. G. (2013). Dendritic Cell Vaccines: Sipuleucel-T and Other Approaches. In Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition (pp. 273-286). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-394296-8.00018-X

Dendritic Cell Vaccines : Sipuleucel-T and Other Approaches. / Durham, Nicholas M.; Drake, Charles G.

Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc., 2013. p. 273-286.

Research output: Chapter in Book/Report/Conference proceedingChapter

Durham, NM & Drake, CG 2013, Dendritic Cell Vaccines: Sipuleucel-T and Other Approaches. in Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc., pp. 273-286. https://doi.org/10.1016/B978-0-12-394296-8.00018-X
Durham NM, Drake CG. Dendritic Cell Vaccines: Sipuleucel-T and Other Approaches. In Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc. 2013. p. 273-286 https://doi.org/10.1016/B978-0-12-394296-8.00018-X
Durham, Nicholas M. ; Drake, Charles G. / Dendritic Cell Vaccines : Sipuleucel-T and Other Approaches. Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc., 2013. pp. 273-286
@inbook{fd9cb658d9aa4f93926193c141f71468,
title = "Dendritic Cell Vaccines: Sipuleucel-T and Other Approaches",
abstract = "The idea of a preventive vaccine against cancer has been extremely attractive because of the immune system's ability to develop specific and long-lasting immunological memory. Dendritic cells, which present antigen to T cells, sit at a critical point in the activation of the immune system because they are able to activate both B cells and T cells. The first DC vaccines were tested in humans in 1998. In 2010 the first DC vaccine was FDA approved for treatment of patients with advanced prostate cancer. This vaccine showed a survival advantage of 4.3 months. This vaccine was extremely safe, with low rates of adverse events. In this chapter we discuss the history of DC vaccines, the development of DC vaccines including Sipuleucel-T, and the future directions of DC vaccines. This includes strategies for combining DC vaccines with other therapies, including hormone therapy, additional immunotherapy, and chemotherapy.",
keywords = "Cancer, Dendritic cells, Hormone therapy, Immunotherapy, Lymphocyte, Sipuleucel-T, Vaccine",
author = "Durham, {Nicholas M.} and Drake, {Charles G.}",
year = "2013",
month = "7",
doi = "10.1016/B978-0-12-394296-8.00018-X",
language = "English (US)",
isbn = "9780123942968",
pages = "273--286",
booktitle = "Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Dendritic Cell Vaccines

T2 - Sipuleucel-T and Other Approaches

AU - Durham, Nicholas M.

AU - Drake, Charles G.

PY - 2013/7

Y1 - 2013/7

N2 - The idea of a preventive vaccine against cancer has been extremely attractive because of the immune system's ability to develop specific and long-lasting immunological memory. Dendritic cells, which present antigen to T cells, sit at a critical point in the activation of the immune system because they are able to activate both B cells and T cells. The first DC vaccines were tested in humans in 1998. In 2010 the first DC vaccine was FDA approved for treatment of patients with advanced prostate cancer. This vaccine showed a survival advantage of 4.3 months. This vaccine was extremely safe, with low rates of adverse events. In this chapter we discuss the history of DC vaccines, the development of DC vaccines including Sipuleucel-T, and the future directions of DC vaccines. This includes strategies for combining DC vaccines with other therapies, including hormone therapy, additional immunotherapy, and chemotherapy.

AB - The idea of a preventive vaccine against cancer has been extremely attractive because of the immune system's ability to develop specific and long-lasting immunological memory. Dendritic cells, which present antigen to T cells, sit at a critical point in the activation of the immune system because they are able to activate both B cells and T cells. The first DC vaccines were tested in humans in 1998. In 2010 the first DC vaccine was FDA approved for treatment of patients with advanced prostate cancer. This vaccine showed a survival advantage of 4.3 months. This vaccine was extremely safe, with low rates of adverse events. In this chapter we discuss the history of DC vaccines, the development of DC vaccines including Sipuleucel-T, and the future directions of DC vaccines. This includes strategies for combining DC vaccines with other therapies, including hormone therapy, additional immunotherapy, and chemotherapy.

KW - Cancer

KW - Dendritic cells

KW - Hormone therapy

KW - Immunotherapy

KW - Lymphocyte

KW - Sipuleucel-T

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84902220042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902220042&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-394296-8.00018-X

DO - 10.1016/B978-0-12-394296-8.00018-X

M3 - Chapter

AN - SCOPUS:84902220042

SN - 9780123942968

SP - 273

EP - 286

BT - Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition

PB - Elsevier Inc.

ER -